From: Vulnerability to stress, anxiety and depressive symptoms and metabolic control in Type 2 diabetes
Model 1 | Model 2 | Model 3 | Model 4 | |
---|---|---|---|---|
Age (years) | 0.92 (0.87-0.96)** | 0.91 (0.86-0.96)** | 0.90 (0.85-0.95)*** | 0.90 (0.85-0.95)*** |
Gender | 0.98 (0.59-1.63) | 1.04 (0.61-1.78) | 1.06 (0.60-1.88) | 1.06 (0.60-1.88) |
Education level (years) | 0.96 (0.91-1.02) | 0.96 (0.91-1.02) | 0.97 (0.91-1.03) | 0.96 (0.89-1.02) |
BMI (kg/m2) | 1.01 (0.95-1.07) | 1.01 (0.95-1.07) | 1.01 (0.95-1.07) | |
Diabetes duration | 1.02 (0.98-1.06) | 1.02 (0.98-1.06) | 1.02 (0.98-1.06) | |
≥ 1 chronic complications | 1.13 (0.66-1.94) | 1.09 (0.63-1.90) | 1.11 (0.64-1.93) | |
Insulin users | 2.69 (1.57-4.59)*** | 2.64 (1.53-4.54)*** | 2.65 (1.54-1.58)*** | |
Antidepressant users | 1.15 (0.50-2.62) | 1.06 (0.45-2.48) | 1.09 (0.46-2.57) | |
HADS depression | 1.13 (1.02-1.24)* | 1.14 (1.03-1.27)** | ||
HADS anxiety | 0.92 (0.84-1.00) | 0.94 (0.85-1.03) | ||
23QVS | 0.98 (0.95-1.01) | |||
Nagelkerke R2 | 0.065 | 0.148 | 0.179 | 0.184 |
Cox&Snell R2 | 0.048 | 0.109 | 0.132 | 0.136 |
Model X2 | 13.4** | 31.6*** | 38.7*** | 39.9*** |